Improving Drug Safety – Without FDA: HHS Adverse Event Report Focuses On Other Agencies
This article was originally published in RPM Report
Executive Summary
HHS is declaring a priority of reducing the burden of adverse events associated with three large classes of drugs: opioids, antidiabetics, and anticoagulants. And, at least in its draft action plan, FDA is not the central actor.